13
Participants
Start Date
September 7, 2021
Primary Completion Date
February 27, 2023
Study Completion Date
January 31, 2026
Pegcetacoplan
Complement (C3) Inhibitor
CHUV, Lausanne
Medical University of Vienna, Vienna
The Royal Melbourne Hospital, Parkville
Monash Medical Centre, Clayton
NYU Langone Health Transplant Insitute, New York
CUIMC, New York
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica
Hospital Universitario 12 de Octubre, Nephrology Department, Madrid
Mayo Clinic, Rochester
Lille Regional University Hospital Center, Claude Huriez Hospital, Department of Nephrology, Lille
Washington University, St.Louis, St Louis
Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon
Children's Hospital Colorado, Aurora
Mayo Clinic Arizona, Phoenix
Keck School of Medicine, University of Southern California, Los Angeles
Hospital de Alta Complejidad en Red El Cruce Dr. Nestor Carlos Kirchner, San Juan Bautista
Hospital Universitario Fundacion Favaloro, Buenos Aires
Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre
UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - FMB/UNESP, Botucatu
Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte
Clinical Research Center, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo
Center Hospitalier Universitaire de Montpellier, Montpellier
Radbound University Medical Center, Nijmegen
Imperial College Healthcare NHS Trust, London
Freeman Hospital, Newcastle upon Tyne
Lead Sponsor
Apellis Pharmaceuticals, Inc.
INDUSTRY